Aurinia Pharmaceuticals

Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Aurinia Pharmaceuticals reports robust Q4 earnings and navigates growth challenges

Aurinia Pharmaceuticals had a strong Q4 performance, with revenue growth and patient access milestones. Despite challenges from COVID-19 and legal disputes, the company remains financially stable and focused on driving growth through patient-centric strategies. Opportunities lie in improving patient adherence and expanding market reach.

Aurinia Pharmaceuticals reports strong Q1 performance and eyes global expansion

Aurinia Pharmaceuticals delivered robust financial performance in Q1 2023, with strong revenue growth and positive patient outcomes.
The company's strategic initiatives and globalization efforts position it well for future growth and market expansion.
Challenges such as slowing new patient starts and persistency caution require focused attention for sustained success.
Opportunities lie in enhancing patient engagement, driving revenue through new patient starts, and strengthening competitive positioning.

Aurinia Pharmaceuticals excels in Q2 earnings, eyes growth opportunities

Aurinia Pharmaceuticals delivered strong financial results in Q2 2023, driven by revenue growth, improved commercial metrics, and effective cost management.
The company's focus on patient awareness, clinical differentiation, and market access for LUPKYNIS positions it well in the competitive landscape of lupus nephritis treatment.
While facing challenges such as seasonality impact and strategic uncertainties, Aurinia remains optimistic about its financial stability, pipeline progress, and growth opportunities.

Aurinia Pharmaceuticals reports strong Q3 performance and explores growth

Aurinia Pharmaceuticals demonstrated robust financial performance and strategic partnerships in Q3 2023, positioning itself for future growth.
While facing challenges in persistency rates and strategic decision-making, the company is leveraging upcoming guidelines and data submissions for market advantage.
Opportunities in education, regulatory approvals, and pricing strategies present avenues for sustained growth and market expansion in the lupus nephritis segment.

Aurinia Pharmaceuticals reports strong Q1 earnings and growth opportunities

Aurinia Pharmaceuticals delivered a robust performance in Q1 2024, driven by strong revenue growth and strategic cost management.
While facing challenges in managing expenses and optimizing patient outcomes, the company remains well-positioned for future profitability.
With a focus on expanding market access, enhancing treatment guidelines, and leveraging its financial strength, Aurinia is poised for continued growth and success.

Aurinia Pharmaceuticals reports robust Q2 revenue growth and strategic initiatives

Aurinia Pharmaceuticals delivered strong financial performance in Q2 2024, with notable revenue growth and operational efficiency.
While facing challenges in revenue guidance and market expectations, the company's strategic initiatives and product adoption present growth opportunities.
With a focus on product development, market expansion, and patient engagement, Aurinia is poised for continued success in the pharmaceutical industry.

Aurinia Pharmaceuticals reports robust Q3 earnings and strategic milestones

Aurinia Pharmaceuticals delivered impressive financial results in Q3 2024, showcasing growth in revenue and operational efficiency.
Despite undergoing a significant restructuring, the company remains focused on innovation, achieving milestones, and expanding its market presence.
With a strong cash position and strategic outlook, Aurinia is poised for continued success and growth in the pharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aurinia Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the trajectory of autoimmune disease, today announced that data from multiple studies of LUPKYNIS® (voclosporin), used to treat adults with active lupus nephritis (LN), a serious complication of systemic lupus erythematosus (SLE), will be presented at American College of Rheumatology (ACR) Convergence 2022.

Aurinia Pharmaceuticals Announces Presentations at American College of Rheumatology (ACR) Convergence 2022

Aurinia Pharmaceutical (AUPH) receives marketing authorization from the European Union for its orally administered CNI immunosuppressant, Lupkynis, for treating lupus nephritis.

Aurinia's (AUPH) Oral Lupus Drug Lupkynis Gets European Approval

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the trajectory of autoimmune disease, announced that the European Commission (EC) has granted marketing authorization of LUPKYNIS® (voclosporin) to treat adults with active lupus nephritis (LN), a serious complication of systemic lupus erythematosus (SLE). The U.S. Food and Drug Administration (FDA) approve

Aurinia Announces European Commission Approval of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis

LUPKYNIS revenues and company net losses are tracking better than my valuation model predicts -- and new European revenues are on the horizon. However, expenses continue to rise, which is contrary to my modelling.

Aurinia Pharmaceuticals: Updating My Revenue And Valuation Model

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH ) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants DeDe Sheel – Vice President-Investor Relations Peter Greenleaf – President and Chief Executive Officer Joe Miller – Chief Financial Officer Neil Solomons – Chief Medical Officer Conference Call Participants Ed Arce – HC Wainwright Justin Kim – Oppenheimer Olivia Brayer – Cantor Fitzgerald Sahil Dhingra – RBC Operator Greetings, and welcome to Aurinia Pharmaceuticals Second Quarter 2022 Financial and Operational Results Conference Call. At this time all participants are in listen-only mode.

Aurinia Pharmaceuticals Inc's (AUPH) CEO Peter Greenleaf on Q2 2022 Results - Earnings Call Transcript

Investors embraced the biotech's second-quarter results.

Why Aurinia Pharmaceuticals Stock Briefly Spiked Today

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Reports Second Quarter and Six Months 2022 Financial and Operational Results

Aurinia Reports Second Quarter and Six Months 2022 Financial and Operational Results

Why Aurinia Pharmaceuticals Stock Is Sliding Today

VICTORIA, British Columbia and ROCKVILLE, Md.--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today received notice regarding the U.S. Patent Office (USPTO) Patent Trial and Appeal Board (PTAB) decision to institute trial on the Inter Partes review (“IPR”) filed by Sun Pharmaceuticals, directed at U.S. Patent No. 10,286,036. This patent is related to the LUPKYNIS® dosing protocol for lupus nephritis. “While this decision is disappointing, as we have st

Aurinia Pharmaceuticals Notification Regarding Inter Partes Patent Review

VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that it will release financial and operational results for the second quarter of 2022 on Thursday, August 4, 2022, before markets open. Aurinia's management team will host a conference call/webcast at 8:30 am ET that day to review these results and provide a general business update. Interested participants can dial 877-407-9170 (Toll-free U.S. &a

Aurinia Pharmaceuticals to Release Second Quarter 2022 Financial and Operational Results on August 4, 2022

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending voclosporin (brand name, LUPKYNIS) for marketing authorization to treat adults with active lupus nephritis (LN), a s

Aurinia Announces Positive CHMP Opinion for LUPKYNIS® (voclosporin) for the Treatment of Adults with Active Lupus Nephritis in Europe

Investors are none too pleased with the company's recent slew of hires.

Why Aurinia Pharmaceuticals Stock Is In Retreat Today

VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today announced the appointment of three seasoned leaders to the Aurinia executive team. Volker Knappertz, MD, will join Aurinia as Executive Vice President (EVP), Research and Development to lead the consolidated Research and Development function. Additio

Aurinia Announces the Addition of Three Seasoned Executive Leaders to Advance Company Strategy and Performance

Aurinia (AUPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Aurinia (AUPH) Moves 13.3% Higher: Will This Strength Last?

Merck

Seagen

The most recent two hottest potatoes in the biotech arena are Aurinia Pharmaceuticals and Seagen. While the latter is mostly/recently associated with an upcoming Merck buyout, the former has been associated with many big pharma names.

A Buyout-Driven Pair Trade: Buy Aurinia, Sell Merck (Or Seagen If You Must)

Another buyout rumor is fueling the company's northward move today.

Why Aurinia Pharmaceuticals Stock Perked Up Today

Los Angeles, California--(Newsfile Corp. - June 14, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aurinia Pharmaceuticals Inc. ("Aurinia" or "the Company") (NASDAQ: AUPH) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between May 7, 2021 and February 25, 2022, inclusive...

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $250,000 to Contact the Firm

NEW YORK , June 14, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) alleging that the Company violated federal securities laws. Class Period: May 7, 2021 to February 25, 2022 Lead Plaintiff Deadline: June 14, 2022 No obligation or cost to you.

AUPH ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 14, 2022 in the Class Action Filed on Behalf of Aurinia Pharmaceuticals Inc. Shareholders

New York, New York--(Newsfile Corp. - June 13, 2022) - Levi & Korsinsky, LLP notifies investors in Aurinia Pharmaceuticals Inc. ("Aurinia Pharmaceuticals Inc." or the "Company") (NASDAQ: AUPH) of a class action securities lawsuit.The lawsuit on behalf of Aurinia Pharmaceuticals Inc. investors has been commenced in the the United States District Court for the Eastern District of New York. Affected investors purchased or otherwise acquired certain Aurinia Pharmaceuticals Inc. securities between May 7, 2021 and...

Aurinia Pharmaceuticals Inc. Class Action: Levi & Korsinsky Reminds Aurinia Pharmaceuticals Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 14, 2022 - AUPH

Los Angeles, California--(Newsfile Corp. - June 13, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aurinia Pharmaceuticals Inc. ("Aurinia" or "the Company") (NASDAQ: AUPH) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between May 7, 2021 and February 25, 2022, inclusive...

DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm

NEW YORK , June 13, 2022 /PRNewswire/ -- Attention Aurinia Pharmaceuticals Inc. ("Aurinia Pharmaceuticals Inc.") (NASDAQ: AUPH) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between May 7, 2021 and February 25, 2022. If you suffered a loss on your investment in Aurinia Pharmaceuticals Inc., contact us about potential recovery by using the link below.

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Aurinia Pharmaceuticals Inc. Investors of a Lead Plaintiff Deadline of June 14, 2022

New York, New York--(Newsfile Corp. - June 12, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) between May 7, 2021 and February 25, 2022, inclusive (the "Class Period"), of the important June 14, 2022 lead plaintiff deadline.SO WHAT: If you purchased Aurinia securities during the Class Period you may be entitled to compensation without payment of any out of pocket...

AUPH FINAL DEADLINE JUNE 14: ROSEN, A TOP RANKED LAW FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important Tuesday Deadline in Securities Class Action - AUPH

Los Angeles, California--(Newsfile Corp. - June 10, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aurinia Pharmaceuticals Inc. ("Aurinia" or "the Company") (NASDAQ: AUPH) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between May 7, 2021 and February 25, 2022, inclusive...

TUESDAY DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm

NEW YORK , June 10, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH). To receive updates on the lawsuit, fill out the form: https://claimyourloss.com/securities/aurinia-pharmaceuticals-inc-loss-submission-form/?id=28308&from=4 The lawsuit seeks to recover losses for shareholders who purchased Aurinia Pharmaceuticals Inc. between May 7, 2021 and February 25, 2022.

AUPH SHAREHOLDER ALERT: Jakubowitz Law Reminds Aurinia Pharmaceuticals Inc. Shareholders of a Lead Plaintiff Deadline of June 14, 2022

San Diego, California--(Newsfile Corp. - June 9, 2022) - Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) securities between May 7, 2021 and February 25, 2022, inclusive (the "Class Period") have until Tuesday, June 14, 2022 to seek appointment as lead plaintiff in Ortmann v. Aurinia Pharmaceuticals Inc., No. 22-cv-01335 (D. Md.). The Aurinia class action lawsuit charges Aurinia and certain of its top executive...

News for Aurinia Pharmaceuticals Stock (AUPH)